PDCD1 and renal cell carcinoma: Recently, cancer immunotherapy including monotherapy1 or combination therapy with anti-PD-1 antibody2 showed better therapeutic effect than molecular-targeted therapies for metastatic renal cell carcinoma (RCC) patients.